Last Updated : March 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Tivicay | Dolutegravir | HIV infection | List | Complete | ||
Toctino | Alitretinoin | Eczema | List with clinical criteria and/or conditions | Complete | ||
Toviaz | Fesoterodine fumarate | Overactive bladder | List in a similar manner | Complete | ||
Trajenta | Linagliptin | Diabetes mellitus, type 2 | List with clinical criteria and/or conditions | Complete | ||
Tramacet | Tramadol hydrochloride /acetaminophen | Acute pain | Do not list | Complete | ||
Translarna | ataluren | Cancelled | ||||
Treanda | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia (relapsed/refractory) | Do not reimburse | Complete | ||
Treanda | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia (first-line) | Reimburse with clinical criteria and/or conditions | Complete | ||
Treanda | Bendamustine hydrochloride | Non-Hodgkin Lymphoma and Mantle Cell Lymphoma | Reimburse | Complete | ||
Treanda (in combination with rituximab) | Bendamustine hydrochloride | Chronic Lymphocytic Leukemia | Withdrawn |